|
An Article from PubMed
Central-NIH National
Library of Medicine on Targeted
treatment of cancer with radiofrequency electromagnetic
fields amplitude-modulated at tumor-specific frequencies
In 2001, Barbault et al.[20] hypothesized that the growth
of human tumors may be sensitive to specific modulation
frequencies. To test this hypothesis, they initiated a
patient-based research using novel biofeedback devices
and techniques, which led to the discovery that patients
with the same tumor type had biofeedback responses to the
same frequencies, irrespective of their sex, age, or ethnic
status[20]. Frequencies identified in patients with cancer
were predominantly found above 1,000 Hz. This range is
significantly higher than the range within which insomnia
frequencies had been identified (<300 Hz). They also
discovered that, in contrast to what had been observed
in patients with insomnia, biofeedback responses were only
observed at very precise frequencies. This prompted the
development of highly precise frequency synthesizers for
the detection of tumor-specific frequencies. Interestingly,
the majority of frequencies identified in a given tumor
type was only found in patients with the same tumor type[20].
For example, 85% of the frequencies identified in patients
with HCC were only found in other patients with HCC. Similarly,
75% of the frequencies identified in patients with breast
cancer were only found in patients with the same tumor
type[20]. They also discovered that a small number of frequencies,
e.g., 1,873.477 Hz, 2,221.323 Hz, 6,350.333 Hz, and 10,456.383
Hz, were found in the majority of patients with breast
cancer, HCC, prostate cancer, and pancreatic cancer[20].
Examination of healthy individuals without a diagnosis
of cancer did not reveal any biofeedback responses to the
frequencies identified in patients with a diagnosis of
cancer.
Then
Royal Rife and Phillip
Hoyland acknowledged all frequencies in their sweep
function
Now
Clinical Experience with Intrabuccal Administration of
Amplitude-modulated Radiofrequency Electromagnetic Fields
After having successfully identified tumor-specific frequencies
in 163 patients with cancer, Barbault et al.[20] offered
compassionate treatment to 28 of these patients with advanced
cancer and limited therapeutic options. Treatment was administered
with a portable device built with the same high precision
frequency synthesizer as that used for the identification
of tumor-specific frequencies. They chose the 27.12 MHz
carrier frequency, as it is universally approved for medical
use. The 27.12 MHz signal was amplitude-modulated at the
specific frequencies identified in patients diagnosed with
cancer. The frequencies were emitted sequentially, each
for 3 s from the lowest to the highest frequency, and the
cycle was continuously repeated for 1 h. Treatment was
administered 3 times a day, i.e., for a total of 3 h until
disease progression or death.
Intrabuccal administration of 27.12 MHz RF EMF with the
TheraBionic device results in a whole body absorption of
very low levels of EMF (Figure 2). The maximum specific
absorption rate of the applied RF averaged over any 10
g of tissue is estimated to be less than 2 W per kg[21].
The results of this study, with a cutoff date of April
1, 2009, are published[20]. Briefly, 1 patient with biopsy-proven
stage IV breast cancer metastasized to the left femur and
right adrenal gland had a complete response lasting 11
months. One patient with biopsy-proven stage IV breast
cancer metastasized to the liver and skeleton had a partial
response lasting 13.5 months. Additionally, 5 patients
had stable disease for +34.1 months (thyroid cancer with
biopsy-proven lung metastases), 6.0 months (mesothelioma
metastasized to the abdomen), 5.1 months (nonsmall cell
lung cancer), and 4.1 months (pancreatic cancer with biopsy-proven
liver metastases). Two patients were still undergoing treatment
as of April 1, 2009. One patient with ovarian cancer refractory
to cisplatin and taxanes underwent treatment for 2 additional
years for a total of 73 months. She had disease progression
and died 78 months after enrolling in the study. The patient
with stage IV thyroid cancer metastasized to the lungs
remains on treatment as October 1, 2013 (Figure 3), and
has received continuous treatment for a total of 86 months.
 |
What
is a Rife Machine?
The Rife
Machine, based on the research of
Dr. Royal Rife, is an innovative device that
has been making waves across various health platforms.
Utilizing cutting-edge technology, this device
has been engineered to deliver exceptional results.
How Does It
Work? See
here for moreinformation
Benifitsb The Benefits of Rife Pro Technology
Support Optimal Wellness: Rife
Technology works by emitting specific frequencies that resonate
with the body's natural energy field, helping
to restore balance and harmony within the body
One of the most remarkable benefits of Rife
Pro Technology is its ability to support
natural processes. Studies have shown that Rife
Technology
can play a role in promoting the death of unhealthy
cells, including tumors, while supporting the
health of surrounding tissue. More information click
here
|
Clinical improvement has been observed within a few weeks
of treatment initiation. Two patients with painful breast
cancer bone metastases experienced significant symptomatic
improvement within 2 weeks[20]. Similarly, among 11 patients
with advanced HCC and pain prior to treatment initiation,
5 reported complete disappearance and 2 reported significant
alleviation of pain within a few weeks of treatment initiation[21]
Patient receives
low levels of EMF that are minimally absorbed and distributed
systemically with the body acting
as an antenna. Yellow indicates the regions of the body
receiving the greatest exposure.
Using the Magnacoil to
deliver pre set, pulsed radiofrequency electromagnetic
fields amplitude-modulated at tumor-specific frequencies
And TENS pads to Deliver pulsed radiofrequency , amplitude-modulated
at tumor-specific frequencies, at the same time
Conclusions
In summary, our clinical results provide strong evidence
that the intrabuccal administration
of RF EMF amplitude-modulated at tumor-specific frequencies
is safe and well-tolerated and may lead to long lasting
therapeutic responses in patients with advanced cancer. Our
in vitro experiments demonstrate that cancer cell proliferation
can be targeted using tumor-specific modulation frequencies,
which were identified in patients diagnosed with cancer.
Tumor-specific modulation frequencies block the growth
of cancer cells, modify gene expression, and disrupt the
mitotic spindle (Figure 6). Studies are underway to dissect
the biophysical mechanism leading cancer cells to respond
to specific modulation frequencies identified in patients
with a corresponding diagnosis of cancer but not to randomly
selected or tumor-specific frequencies identified in other
tum
Using
the Magnacoil to deliver pre set, pulsed radiofrequency
electromagnetic fields amplitude-modulated at tumor-specific
frequencies .And TENS pads to Deliver pulsed radiofrequency
, amplitude-modulated at tumor-specific frequencies,
All at the same time Many thanks to the clients who
donated their pictures
The Rife 2H- 4H Systems below has a frequency "set",
that includes all the above frequencies pre programed,
and uses "electromagnetic fields amplitude-modulated
at tumor-specific frequencies" or if required intrabuccal
administration of RF EMF frequencies...
If you Already have one of our Rife 2h-4h Systems
this set of frequencies is listed on the hoyland software,
under "tumors". The article
suggest one runs these frequencies 3 times a day..
Please
help, share this Newsletter to family and friends.
Every thing Listed in each individual option
is what is sent...
|
